Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease.

@article{SllosMoura2011DevelopmentOA,
  title={Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease.},
  author={M{\'a}rcia S{\'e}llos-Moura and Samad Barzegar and Luying Pan and Philip Shi and Susan Oommen and Judith Durant and Juan Antonio Ruiz},
  journal={Journal of immunological methods},
  year={2011},
  volume={373 1-2},
  pages={45-53}
}
Anti-drug antibodies are elicited by virtually all therapeutic proteins, and standardized assays are required for clinical monitoring of patients as well as for comparing antibody response to different therapeutic proteins in clinical trials. Velaglucerase alfa and imiglucerase are enzyme replacement therapies for the long-term treatment of type 1 Gaucher disease, a lysosomal storage disease resulting from an inherited deficiency of the enzyme glucocerebrosidase. We used state-of-the-art tools… CONTINUE READING
10 Extracted Citations
17 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 10 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 17 references

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use

  • M. Liang, S. L. Klakamp, +9 authors L. K. Roskos
  • 2007
1 Excerpt

Similar Papers

Loading similar papers…